iNEXT and Industry
The iNEXT consortium is pioneering coordinated access to infrastructures for macromolecular crystallography, SAXS, NMR, electron microscopy, advanced light microscopy and biophysics. The aim of this initiative is to facilitate the structural and functional analysis of complex biological systems and to promote translational research in the biomedicine and biotechnology sectors. Scientists in industry have been major users of some of these infrastructures over the years. For example, synchrotrons for macromolecular crystallography and NMR facilities have become an integral part of many drug development programs. On the other hand new structural biology methods, like those based on electron microscopy are rapidly becoming relevant for the field.
Access, training and research
iNEXT aims at providing an effective link between scientists from academia and industry by facilitating access to high-end facilities, and by providing Enhanced Support access modes for researchers without prior experience in the field. The latter are addressed to scientists from other fields than structural biology and commercial parties that might not run an in-house structural biology program (SME). Access to iNEXT facilities is in principle trans-national and free of charge. In some cases access providers may also cover traveling and accommodation expenses. The results of the access must be disseminated via open access scientific publications, the research data supporting the publication should be deposited.
In addition to access, the consortium has established ambitious collaborative structural biology research programs to develop advanced methodologies for ligand screening, the study of membrane proteins and acquiring structural information in the context of the living cell.
iNEXT Industrial Platform
In order to foster and promote its impact in applied research programs, the iNEXT consortium has established an Industrial Platform composed of renowned experts from the private sector. This panel will help the consortium in establishing effective communication gateways with industry.
Industrial Platform members
Dr. Marcel Blommers, Co-founder / Director, Saverna Therapeutics, Basel, Switzerland
Dr. Ilaria Ferlenghi, Senior Research Investigator, Protein Biochemistry, Glaxo SmithKline, Siena, Italy
Dr. Matthias Frech, Director of Molecular Interactions and Biophysics. Merck-Serono, Darmstadt, Germany
Dr. Magali Mathieu, Structural Biology and Biophysics, Sanofi, Vitry-sur-Seine, France
Dr. Thomas Bertrand, Structural Biology and Biophysics, Sanofi, Vitry-sur-Seine, France
Dr. Marc O’Reilly, Director of Moleular Sciences, Astex Pharmaceuticals, Cambridge, UK
Dr. Marc Storms, Marketing Manager Life Sciences, FEI Company, Eindhoven, NL
Dr. Björn Walse, Founder / CEO, SARomics Biostructures AB, Lund, Sweden